News from novo nordisk A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

30 Apr, 2019, 08:00 BST Novo Nordisk to achieve target of 100% renewable power in production and launches new ambition aiming for zero environmental impact

Novo Nordisk today announced that it will achieve its target to use only renewable electricity in its global production facilities by 2020. The...


23 Mar, 2019, 18:00 GMT Oral semaglutide 7 mg and 14 mg doses showed superior reductions in blood sugar and weight compared to sitagliptin at 26 weeks in data presented at ENDO

Oral semaglutide 7 mg and 14 mg demonstrated superior HbA1c and body weight reductions compared to Januvia® (sitagliptin 100 mg). Non-inferiority for ...


08 Mar, 2019, 00:01 GMT Insulin Degludec Significantly Reduces the Risk of Hypoglycaemia When People With Diabetes Switch From Other Basal Insulins in a Real-world Setting

Findings from ReFLeCT – a large non-interventional real-world study using patient diaries – were presented today at the Diabetes UK Professional...


04 Mar, 2019, 13:00 GMT Ozempic® Superior in Lowering Blood Sugar and Weight Vs Placebo, Both in Combination with SGLT-2 Inhibitors

Novo Nordisk today announced publication of results from the SUSTAIN 9 Phase 3b trial in The Lancet Diabetes & Endocrinology. The objective of this...


02 Oct, 2018, 10:59 BST Ryzodeg® Offers a Simpler Solution With Once-Daily Dosing and Reduced Risk of Nocturnal Hypoglycaemia vs Insulin Glargine U100 Plus Insulin Aspart

When treated with once-daily Ryzodeg®, people with type 2 diabetes achieved similar blood sugar control with half the number of daily injections,...


02 Oct, 2018, 10:59 BST Addressing Social and Cultural Drivers of Type 2 Diabetes is Key to Its Treatment and Prevention

New research shows healthcare services and public health strategies aimed at reducing the burden of type 2 diabetes may prove ineffective, unless...


02 Oct, 2018, 10:59 BST People With Diabetes May Achieve Improved Glycaemic Control With Tresiba® Versus Glargine U100, Without an Increase in Hypoglycaemia

According to results of a post-hoc analysis people with both type 1 and type 2 diabetes in clinical practice may achieve improved glycaemic control...


28 Sep, 2018, 09:00 BST International Diabetes Federation (IDF) Global Survey Reveals 2 in 3 People With Type 2 Diabetes Have Cardiovascular Disease Risk Factors and/or Have Experienced a Cardiovascular Event

Cardiovascular disease (CVD) is the leading cause of disability and death in people with type 2 diabetes[1] Despite the high incidence, 1 in 4 people ...


28 Sep, 2018, 07:40 BST New Phase 2 Data for Somapacitan Demonstrate Its Potential as an Efficacious Once-weekly Treatment for Childhood Growth Hormone Deficiency

Somapacitan, a novel growth hormone derivative in development for once-weekly administration of growth hormone, matched the therapeutic benefits of...


26 Aug, 2018, 13:00 BST Ozempic® Consistently Reduced the Risk of Major Cardiovascular Events Across Type 2 Diabetes Populations at High CV Risk Regardless of Prior CV Events at Baseline

Ozempic® (semaglutide) consistently reduced the risk of the composite outcome of time to first occurrence of non-fatal heart attack, non-fatal stroke ...


23 Jun, 2018, 15:12 BST Tresiba® Demonstrated Significantly Improved Blood Sugar Control and Lower Rates of Hypoglycaemia Versus Insulin Glargine U300 in Real-World Evidence Study

Adults with type 2 diabetes treated with Tresiba® (insulin degludec injection) had a significant reduction in HbA1c and a 30% lower rate of...


23 Jun, 2018, 15:09 BST Ozempic® Provided Greater Weight Reductions for Adults With a Baseline BMI ≥25kg/m2 Than Those With Lower Baseline BMI <25kg/m2, in a SUSTAIN 7 Post-hoc Analysis

Poster Presentation #1083-P Ozempic® (semaglutide) 0.5 mg or 1.0 mg provided greater weight reductions vs dulaglutide 0.75 mg or 1.5 mg,...


23 Jun, 2018, 15:06 BST Oral Semaglutide Demonstrated Significant Reduction in Blood Sugar vs Placebo in PIONEER 1 Trial

Oral semaglutide, an investigational GLP-1 analogue taken as a once-daily tablet, achieved significant reductions in blood sugar versus placebo in...


23 Jun, 2018, 13:05 BST Significant Blood Sugar Improvement With Xultophy® Compared to Insulin Glargine U-100 When Used as Add-On to Oral Diabetes Medications

Oral Presentation #127-OR Adults with type 2 diabetes treated with Xultophy® (insulin degludec and liraglutide injection) also experienced no change...


24 May, 2018, 07:00 BST Real-World Evidence Shows Clinically Meaningful Weight Loss in People Receiving Saxenda®

People treated with Saxenda® (liraglutide 3 mg) for weight management lost an average of 8.1 kg after six months in a real-world clinical setting, in ...


21 May, 2018, 10:45 BST Head-to-Head Trial Shows Refixia® Achieves Greater Total Factor IX Exposure in People With Haemophilia B Than Recombinant Factor IX-Fc Fusion Protein

Adults with haemophilia B who received a single dose Refixia® (nonacog beta pegol; N9-GP) achieved greater total factor IX exposure than those...


21 May, 2018, 09:00 BST NovoEight® Maintains Potency When Stored at 40ºC Offering People With Haemophilia A Increased Flexibility in Their Daily Lives

A new long term stability study has shown that haemophilia A treatment NovoEight® (turoctocog alfa) remains potent after three months exposure to...


19 Mar, 2018, 12:00 GMT Semaglutide Injection Phase 2 Data Presented at ENDO Demonstrated Significant Weight Loss in Adults With Obesity

Oral session #12 Adults with obesity treated with semaglutide 0.4 mg administered once-daily via subcutaneous injections lost up to 13.8% of their...


01 Feb, 2018, 08:30 GMT Semaglutide Demonstrated Significant Reductions in Blood Sugar and Weight Compared with Dulaglutide; Results Published in The Lancet Diabetes & Endocrinology

Results from the SUSTAIN 7 trial, which investigated the efficacy and safety of 0.5 mg semaglutide compared with 0.75 mg dulaglutide and 1.0 mg...


11 Dec, 2017, 08:00 GMT Xultophy® Significantly Reduces Blood Sugar Levels, Body Weight and Risk of Hypoglycaemia for People With Type 2 Diabetes in Real-World Setting

Results published in Diabetes, Obesity and Metabolism Newly published data from real-world European clinical practice has shown that Xultophy®...


07 Dec, 2017, 08:45 GMT Ryzodeg® Significantly Reduces the Risk of Low Blood Sugar in People With Type 2 Diabetes who Fast During Ramadan

In people with type 2 diabetes who fast during Ramadan, Ryzodeg® (insulin degludec/insulin aspart) reduced the overall rate of low blood sugar...


07 Dec, 2017, 08:45 GMT Tresiba® Reduces Hypoglycaemia Regardless of Blood Sugar Level

People with either type 1 or type 2 diabetes treated with Tresiba® had fewer episodes of low blood sugar (hypoglycaemia) compared with people on...


06 Dec, 2017, 08:01 GMT Interim Results of First-Ever Global Survey Show People with Type 2 Diabetes Underestimate their Cardiovascular Risk

Globally, cardiovascular disease (CVD) is the most common cause of death in people with type 2 diabetes[1] 1 in 3 respondents considered themselves...


05 Dec, 2017, 09:00 GMT Switching to Tresiba® Benefits People with Diabetes Irrespective of Blood Sugar Levels in a Real-world Setting

Switching to Tresiba® reduced the rate of hypoglycaemia by 67% in people with controlled blood sugar levels In people with diabetes whose blood sugar ...


05 Dec, 2017, 06:00 GMT Xultophy® Reported a Better Option than Basal-Bolus Insulin Therapy to Manage Type 2 Diabetes by Participants in the DUAL VII Clinical Trial

Once-daily Xultophy® (insulin degludec/liraglutide) was a better option to manage diabetes compared to multiple daily injections of insulin...